Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of ENB-006-09: Long-Term Safety and PK of Subcutaneous Asfotase Alfa
2017-003153-42Phase 2
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asfotase alfa in hypophosphatasia (HPP), sponsored by Alexion Pharmaceuticals. Primary endpoint: Long-term tolerability of subcutaneous asfotase alfa.
02
Drugs
asfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2017-003153-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003153-42.